Sarasin & Partners’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $94.7M | Sell |
736,662
-49,029
| -6% | -$5.74M | 1.11% | 31 |
|
|
2026
Q1 | $94.5M | Sell |
785,691
-129,503
| -14% | -$15M | 1.15% | 29 |
|
|
2025
Q4 | $96.3M | Sell |
915,194
-32,675
| -3% | -$3.07M | 1% | 32 |
|
|
2025
Q3 | $74.5M | Buy |
947,869
+773
| +0.1% | +$63.7K | 0.73% | 35 |
|
|
2025
Q2 | $75M | Buy |
947,096
+20,446
| +2% | +$1.63M | 0.75% | 36 |
|
|
2025
Q1 | $83.2M | Buy |
926,650
+38,149
| +4% | +$3.56M | 0.9% | 33 |
|
|
2024
Q4 | $88.4M | Sell |
888,501
-995,784
| -53% | -$103M | 0.98% | 27 |
|
|
2024
Q3 | $214M | Sell |
1,884,285
-384,077
| -17% | -$45.6M | 2.02% | 23 |
|
|
2024
Q2 | $281M | Sell |
2,268,362
-539,785
| -19% | -$69.5M | 2.49% | 19 |
|
|
2024
Q1 | $371M | Sell |
2,808,147
-49,648
| -2% | -$6.12M | 3.65% | 8 |
|
|
2023
Q4 | $312M | Sell |
2,857,795
-439,635
| -13% | -$45.6M | 3.43% | 8 |
|
|
2023
Q3 | $339M | Buy |
3,297,430
+104,812
| +3% | +$11.3M | 4.24% | 6 |
|
|
2023
Q2 | $368M | Sell |
3,192,618
-4,081,627
| -56% | -$463M | 4.27% | 6 |
|
|
2023
Q1 | $667M | Buy |
7,274,245
+4,126,064
| +131% | +$445M | 3.59% | 5 |
|
|
2022
Q4 | $349M | Sell |
3,148,181
-506,208
| -14% | -$51.7M | 4.57% | 3 |
|
|
2022
Q3 | $315M | Sell |
3,654,389
-109,832
| -3% | -$9.8M | 4.36% | 2 |
|
|
2022
Q2 | $343M | Sell |
3,764,221
-1,139,901
| -23% | -$101M | 4.33% | 3 |
|
|
2022
Q1 | $402M | Buy |
4,904,122
+829,901
| +20% | +$65.4M | 4.05% | 3 |
|
|
2021
Q4 | $312M | Buy |
4,074,221
+333,906
| +9% | +$26.6M | 2.84% | 11 |
|
|
2021
Q3 | $281M | Buy |
3,740,315
+298,313
| +9% | +$22.7M | 2.84% | 12 |
|
|
2021
Q2 | $268M | Buy |
3,442,002
+343,025
| +11% | +$25.5M | 2.79% | 14 |
|
|
2021
Q1 | $228M | Buy |
3,098,977
+558,567
| +22% | +$41.2M | 2.69% | 16 |
|
|
2020
Q4 | $198M | Buy |
2,540,410
+176,079
| +7% | +$13.5M | 2.62% | 16 |
|
|
2020
Q3 | $187M | Buy |
2,364,331
+462,515
| +24% | +$36.2M | 2.71% | 13 |
|
|
2020
Q2 | $140M | Buy |
1,901,816
+1,561,226
| +458% | +$118M | 2.24% | 20 |
|
|
2020
Q1 | $25M | Buy |
340,590
+262,314
| +335% | +$20.6M | 0.49% | 43 |
|
|
2019
Q4 | $6.79M | Hold |
78,276
| – | – | 0.1% | 84 |
|
|
2019
Q3 | $6.29M | Buy |
78,276
+13,140
| +20% | +$1.05M | 0.1% | 85 |
|
|
2019
Q2 | $5.21M | Buy |
65,136
+25,774
| +65% | +$1.97M | 0.09% | 91 |
|
|
2019
Q1 | $3.12M | Hold |
39,362
| – | – | 0.06% | 96 |
|
|
2018
Q4 | $2.87M | Sell |
39,362
-17,516
| -31% | -$1.24M | 0.06% | 96 |
|
|
2018
Q3 | $3.85M | Buy |
+56,878
| New | +$3.62M | 0.07% | 96 |
|
Other funds holding MRK
ATO
Sarasin & Partners's MRK Position: Q2 2026 in Review
Sarasin & Partners reduced its Merck (MRK) stake by 6.2% in Q2 2026, selling an estimated $5.74M and leaving 736,662 shares worth $94.7M. The position accounts for 1.11% of the portfolio, ranked #31.
Sarasin & Partners first reported a position in MRK in Q3 2018 and has held it in 32 quarters since. The position peaked at $667M in Q1 2023. 1,503 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Sarasin & Partners held 736,662 shares of Merck worth $94.7M as of Q2 2026.
- Sarasin & Partners sold 49,029 Merck shares in Q2 2026, an estimated $5.74M.
- Merck made up 1.11% of Sarasin & Partners's portfolio in Q2 2026, its #31 holding.
- Sarasin & Partners first reported a position in Merck in Q3 2018 and has held it in 32 quarters since.
- Sarasin & Partners's Merck position peaked at $667M in Q1 2023.
- 1,503 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Sarasin & Partners's 13F filing for Q2 2026, filed 7 Jul 2026.